Opendata, web and dolomites

AXONE SIGNED

Commercial multiple electrode lead technology for cardiac disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AXONE project word cloud

Explore the words cloud of the AXONE project. It provides you a very rough idea of what is the project "AXONE" about.

coronary    generates    compete    axone    perform    sales    effect    positive    depending    70    heart    definition    direct    previously    50    vein    vary    patients    2020    site    commercial    spaced    left    plan    stimulate    marking    people    diameter    efficiency    revenues    yearly    procedure    placed    ce    finalize    opportunity    82    crt    leaving    single    2026    responder    file    individual    manufacture    therapy    market    class    finalise    initiated    advantages    times    medical    benefits    impressive    implantation    combines    million    clinical    commercialisation    companies    give    sites    reducing    commercialization    rate    14    performance    resynchronization    device    place    pacing    ventricle    is4    validation    chronic    start    prepare    decrease    25    projected    marketing    selling    confirm    pacemaker    smaller    cardiac    population    generation    industrialization    launch    dominated    capability    acute    healthcare    considerably    time    leads    global   

Project "AXONE" data sheet

The following table provides information about the project.

Coordinator
SORIN CRM SAS 

Organization address
address: AVENUE REAUMUR 4
city: CLAMART
postcode: 92140
website: www.sorin-crm.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.crm.microport.com/
 Total cost 3˙513˙187 €
 EC max contribution 2˙694˙187 € (77%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2. (PRIORITY 'Industrial leadership')
 Code Call H2020-FTIPilot-2016-1
 Funding Scheme IA
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2019-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SORIN CRM SAS FR (CLAMART) coordinator 1˙373˙312.00
2    HERAEUS DEUTSCHLAND GMBH & CO KG DE (HANAU) participant 537˙687.00
3    CENTRE HOSPITALIER UNIVERSITAIRE DE ROUEN FR (ROUEN) participant 425˙062.00
4    UNIVERSITEIT MAASTRICHT NL (MAASTRICHT) participant 358˙125.00

Map

 Project objective

Heart failure affects more than 14 million people in Europe, and is projected to affect about 30 million people by 2020. While the effects of Cardiac Resynchronization Therapy on the wider heart failure population are impressive, benefits at the individual level vary considerably. Depending on the definition, the responder rate CRT is positive in 50-70% of patients, leaving 30-50% without any significant effect. This project will finalise the development of a pacemaker cardiac lead that is 5 times smaller diameter than the state-of-the-art, and start the commercialisation of the product. The project will directly improve the efficiency of Cardiac Resynchronization Therapy (CRT) by reducing the time required for the implantation procedure by 25%, and decrease the yearly healthcare costs by 82 M€/year in Europe. In addition, the project will help European companies to compete in the pacemaker market currently dominated by US companies. Axone IS4 lead combines the advantages of a single lead, which is easy to place in any coronary vein, with the capability to stimulate the left ventricle at 2 widely spaced sites for a more global resynchronization – this has previously required 2 leads to be placed in the heart. The objective of the AXONE project is to: • Finalize product industrialization. • Confirm chronic pre-clinical performance with large scale studies. • Perform an acute clinical study and a chronic clinical validation. • Manufacture clinical and commercial products. • Build the marketing plan and prepare the product launch. • File CE marking of the class III medical device system. • Launch the commercialization of AXONE system and start selling the system in Europe. This novel approach of multi-site pacing has the potential to become the next CRT therapy device generation, initiated in Europe. This project will give an opportunity to generates 90 M€ direct revenues sales in 2026.

 Deliverables

List of deliverables.
Final acute clinical study report Documents, reports 2019-05-31 10:02:15
AXONE benefit over standard CRT report Documents, reports 2019-05-31 10:02:12
Preclinical safety performance report Documents, reports 2019-05-31 10:02:12

Take a look to the deliverables list in detail:  detailed list of AXONE deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AXONE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AXONE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.)

Innovation Principle (2019)

Developing an Innovation-Friendly Legislative Culture – the Innovation Principle at Work

Read More  

PULSe (2017)

Pervasive Ubiquitous Lightwave SEnsor

Read More  

BIOCOMPLACK (2016)

Eco-friendly food packaging with enhanced barrier properties

Read More